Michael R. Hayden - Aug 8, 2023 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role: Director
Signature: Tryn Stimart, attorney-in-fact
Stock symbol: ABCL
Transactions as of: Aug 8, 2023
Transactions value $: $177,000
Form type: 4
Date filed: 8/9/2023, 12:22 PM
Previous filing: Jul 19, 2023
Next filing: Sep 26, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABCL	Common Shares	Purchase	$177K	+30K	+2.36%	$5.90	1.3M	Aug 8, 2023	See footnote	F1, F2
holding	ABCL	Common Shares						118K	Aug 8, 2023	By spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $5.89 to $5.91. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
F2	These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.

Content

The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $5.89 to $5.91. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.